Lotus Pharmaceutical Co., Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
entacapone(Comtess)
Approved
COMTSmall molecule
Parkinson's Disease
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
May 2027 (1)
SerplulimabPhase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
June 2027 (1)
SerplulimabPhase 2Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
July 2027 (1)
SerplulimabPhase 1/2Colon Cancer Adenocarcinoma
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
December 2027 (1)
SerplulimabPhase 2Carcinoma of Head and/or Neck
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
SerplulimabPhase 2/3Squamous NSCLC
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.